You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 255 No. 2, January 10, 1986 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL INVESTIGATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Demonstration of Inhibition of Mediator Release From Human Mast Cells by Azatadine Base

In Vivo and In Vitro Evaluation

Alkis G. Togias, MD; Robert M. Naclerio, MD; Jane Warner, PhD; David Proud, PhD; Anne Kagey-Sobotka, PhD; Indira Nimmagadda; Philip S. Norman, MD; Lawrence M. Lichtenstein, MD, PhD

JAMA. 1986;255(2):225-229.


Abstract

In vitro experimentation using dispersed human lung mast cells demonstrated that azatadine base, a compound with known H1-antihistamine properties, inhibited anti-IgE-induced release of histamine and leukotriene C4 by 45% and 85%, respectively. To assess the clinical relevance of these findings and to compare in vitro mast cell data with results obtained in vivo, nasally instilled azatadine was tested in a double-blind, placebo-controlled clinical trial in which nasal challenges with antigen were performed on eight allergic individuals. Pretreatment with azatadine significantly suppressed the number of sneezes following antigen challenge and inhibited the associated elevations in histamine, kinins, and enzyme(s) hydrolyzing the artificial substrate N-{alpha}-tosyl-L-arginine-methyl-ester in nasal secretions, whereas placebo was inactive. Hence, we showed agreement between our in vitro and in vivo experimental models of the allergic reaction. Topical application of azatadine base has the potential to become an effective antiallergic treatment.

(JAMA 1986;255:225-229)



Author Affiliations

From the Departments of Medicine (Drs Togias, Warner, Proud, Kagey-Sobotka, Norman, and Lichtenstein and Ms Nimmagadda) and Otolaryngology (Dr Naclerio), The Johns Hopkins University School of Medicine at The Good Samaritan Hospital, Baltimore.


Footnotes

Reprint requests to Division of Clinical Immunology, The Johns Hopkins University School of Medicine at The Good Samaritan Hospital, 5601 Loch Raven Blvd, Baltimore, MD 21239 (Dr Togias).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rhinitis and Asthma
Kaliner et al.
JAMA 1987;258:2851-2873.
ABSTRACT  

Allergy and Antihistamines: A New Riddle
Theoharides
Arch Dermatol 1986;122:995-996.
ABSTRACT  

Inhibition of Mediator Release in Azatadine
Lehrer
JAMA 1986;255:3366-3367.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.